Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma.
Publication/Presentation Date
6-1-2015
Abstract
The primary objective of the study was to evaluate the feasibility and safety of a process which would utilize genome-wide expression data from tumor biopsies to support individualized treatment decisions. Current treatment options for recurrent neuroblastoma are limited and ineffective, with a survival rate of
Volume
4
Issue
6
First Page
871
Last Page
886
ISSN
2045-7634
Published In/Presented At
Saulnier Sholler, G. L., Bond, J. P., Bergendahl, G., Dutta, A., Dragon, J., Neville, K., Ferguson, W., Roberts, W., Eslin, D., Kraveka, J., Kaplan, J., Mitchell, D., Parikh, N., Merchant, M., Ashikaga, T., Hanna, G., Lescault, P. J., Siniard, A., Corneveaux, J., Huentelman, M., … Trent, J. (2015). Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. Cancer medicine, 4(6), 871–886. https://doi.org/10.1002/cam4.436
Disciplines
Medicine and Health Sciences | Pediatrics
PubMedID
25720842
Department(s)
Department of Pediatrics
Document Type
Article